Resistance to Anti-EGFR therapy in colorectal cancer: From heterogeneity to convergent evolution

Sandra Misale, Federica Di Nicolantonio, Andrea Sartore-Bianchi, Salvatore Siena, Alberto Bardelli

Research output: Contribution to journalArticle

Abstract

The EGFR-targeted antibodies cetuximab and panitumumab are used to treat metastatic colorectal cancers. Mutations in K RAS, N RAS, and B RAF and amplifi-cation of ERBB2 and MET drive primary (de novo) resistance to anti-EGFR treatment. Recently, the emergence of alterations in the same genes was detected in patients who responded to EGFR blockade and then relapsed. These results illuminate a striking overlap between genes that, when mutated, drive primary and secondary resistance to anti-EGFR antibodies. Remarkably, although the mechanisms of resistance are genetically heterogeneous, they biochemically converge on key signaling pathways. This knowledge is being translated in the rational design of additional lines of therapy.

Significance: Anti-EGFR-targeted therapies are used for the treatment of metastatic colorectal cancer. Molecular heterogeneity impairs their efficacy by fuelling de novo and acquired resistance. In this review, we highlight how genetically distinct resistance mechanisms biochemically converge on a limited number of signaling pathways that can be therapeutically intercepted.

Original languageEnglish
Pages (from-to)1269-1280
Number of pages12
JournalCancer Discovery
Volume4
Issue number11
DOIs
Publication statusPublished - Nov 1 2014

Fingerprint

Colorectal Neoplasms
Therapeutics
Genes
Cations
Anti-Idiotypic Antibodies
Mutation
Antibodies

ASJC Scopus subject areas

  • Oncology
  • Medicine(all)

Cite this

Resistance to Anti-EGFR therapy in colorectal cancer : From heterogeneity to convergent evolution. / Misale, Sandra; Di Nicolantonio, Federica; Sartore-Bianchi, Andrea; Siena, Salvatore; Bardelli, Alberto.

In: Cancer Discovery, Vol. 4, No. 11, 01.11.2014, p. 1269-1280.

Research output: Contribution to journalArticle

Misale, Sandra ; Di Nicolantonio, Federica ; Sartore-Bianchi, Andrea ; Siena, Salvatore ; Bardelli, Alberto. / Resistance to Anti-EGFR therapy in colorectal cancer : From heterogeneity to convergent evolution. In: Cancer Discovery. 2014 ; Vol. 4, No. 11. pp. 1269-1280.
@article{d07dac5b1fb24eefb5ce9cb927a49f19,
title = "Resistance to Anti-EGFR therapy in colorectal cancer: From heterogeneity to convergent evolution",
abstract = "The EGFR-targeted antibodies cetuximab and panitumumab are used to treat metastatic colorectal cancers. Mutations in K RAS, N RAS, and B RAF and amplifi-cation of ERBB2 and MET drive primary (de novo) resistance to anti-EGFR treatment. Recently, the emergence of alterations in the same genes was detected in patients who responded to EGFR blockade and then relapsed. These results illuminate a striking overlap between genes that, when mutated, drive primary and secondary resistance to anti-EGFR antibodies. Remarkably, although the mechanisms of resistance are genetically heterogeneous, they biochemically converge on key signaling pathways. This knowledge is being translated in the rational design of additional lines of therapy.Significance: Anti-EGFR-targeted therapies are used for the treatment of metastatic colorectal cancer. Molecular heterogeneity impairs their efficacy by fuelling de novo and acquired resistance. In this review, we highlight how genetically distinct resistance mechanisms biochemically converge on a limited number of signaling pathways that can be therapeutically intercepted.",
author = "Sandra Misale and {Di Nicolantonio}, Federica and Andrea Sartore-Bianchi and Salvatore Siena and Alberto Bardelli",
year = "2014",
month = "11",
day = "1",
doi = "10.1158/2159-8290.CD-14-0462",
language = "English",
volume = "4",
pages = "1269--1280",
journal = "Cancer Discovery",
issn = "2159-8274",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - Resistance to Anti-EGFR therapy in colorectal cancer

T2 - From heterogeneity to convergent evolution

AU - Misale, Sandra

AU - Di Nicolantonio, Federica

AU - Sartore-Bianchi, Andrea

AU - Siena, Salvatore

AU - Bardelli, Alberto

PY - 2014/11/1

Y1 - 2014/11/1

N2 - The EGFR-targeted antibodies cetuximab and panitumumab are used to treat metastatic colorectal cancers. Mutations in K RAS, N RAS, and B RAF and amplifi-cation of ERBB2 and MET drive primary (de novo) resistance to anti-EGFR treatment. Recently, the emergence of alterations in the same genes was detected in patients who responded to EGFR blockade and then relapsed. These results illuminate a striking overlap between genes that, when mutated, drive primary and secondary resistance to anti-EGFR antibodies. Remarkably, although the mechanisms of resistance are genetically heterogeneous, they biochemically converge on key signaling pathways. This knowledge is being translated in the rational design of additional lines of therapy.Significance: Anti-EGFR-targeted therapies are used for the treatment of metastatic colorectal cancer. Molecular heterogeneity impairs their efficacy by fuelling de novo and acquired resistance. In this review, we highlight how genetically distinct resistance mechanisms biochemically converge on a limited number of signaling pathways that can be therapeutically intercepted.

AB - The EGFR-targeted antibodies cetuximab and panitumumab are used to treat metastatic colorectal cancers. Mutations in K RAS, N RAS, and B RAF and amplifi-cation of ERBB2 and MET drive primary (de novo) resistance to anti-EGFR treatment. Recently, the emergence of alterations in the same genes was detected in patients who responded to EGFR blockade and then relapsed. These results illuminate a striking overlap between genes that, when mutated, drive primary and secondary resistance to anti-EGFR antibodies. Remarkably, although the mechanisms of resistance are genetically heterogeneous, they biochemically converge on key signaling pathways. This knowledge is being translated in the rational design of additional lines of therapy.Significance: Anti-EGFR-targeted therapies are used for the treatment of metastatic colorectal cancer. Molecular heterogeneity impairs their efficacy by fuelling de novo and acquired resistance. In this review, we highlight how genetically distinct resistance mechanisms biochemically converge on a limited number of signaling pathways that can be therapeutically intercepted.

UR - http://www.scopus.com/inward/record.url?scp=84908431348&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908431348&partnerID=8YFLogxK

U2 - 10.1158/2159-8290.CD-14-0462

DO - 10.1158/2159-8290.CD-14-0462

M3 - Article

C2 - 25293556

AN - SCOPUS:84908431348

VL - 4

SP - 1269

EP - 1280

JO - Cancer Discovery

JF - Cancer Discovery

SN - 2159-8274

IS - 11

ER -